Skip to main content
. Author manuscript; available in PMC: 2026 Feb 1.
Published in final edited form as: J Clin Oncol. 2024 Oct 2;43(4):432–442. doi: 10.1200/JCO.24.00640

Figure 2. Kaposi sarcoma responses and progression-free survival.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Panel A shows a swimmer’s plot of participant responses. Each bar represents one participant, blue circles indicate time of partial response which is plotted until progressive disease or the last KS response assessment, whichever occurred later. Arrows indicate ongoing partial response at the time of data cut-off. The darker gray indicates the duration of response. Panel B shows the progression-free survival in all participants with response evaluable Kaposi sarcoma. Panel C shows the progression-free survival by CD4+ T-cell count, and Panel D shows the progression-free survival by pembrolizumab as first systemic KS therapy versus second-line or greater therapy.